Cytokines 2022: 10th Annual Meeting of the International Cytokine & Interferon Society
September 20 - September 23, 2022
Hilton Waikoloa Village, Big Island, Hawaii
Posters presented: September 20, 2022
- A Next Generation Bifunctional Superkine for Immunotherapy (BiSKITÔ) Encompassing the Combined Therapeutic Potency of IL-2 Super-Agonist and Anti-PD1
- Fc-MDNA413 is a Novel Long-Acting IL-4/IL-13 Super-Antagonist that Suppresses M2a TAM Skewing and In Vivo Tumor Growth Including Synergy with an IL-2 Super-Agonist.